Format

Send to

Choose Destination
Blood. 2016 Jun 30;127(26):3360-8. doi: 10.1182/blood-2015-11-683854. Epub 2016 May 12.

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.

Author information

1
Institute for Myeloma and Bone Cancer Research, West Hollywood, CA;
2
Comprehensive Blood and Cancer Center, Bakersfield, CA;
3
Cancer Care Associates for Research and Excellence, Encinitas, CA;
4
US Oncology Research and Cancer Care Centers of South Texas, San Antonio, TX;
5
Horizon Oncology Center, Lafayette, IN;
6
Cedars-Sinai Medical Center, Los Angeles, CA;
7
The Oncology Institute of Hope and Innovation, Downey, CA;
8
Center for Cancer and Blood Disorders, Bethesda, MD;
9
Department of Hematology/Oncology, Weill Cornell Medical College, Clinical Research Alliance, New Hyde Park, NY;
10
Robert A. Moss Medical Oncology and Hematology, Fountain Valley, CA;
11
US Oncology Research and Rocky Mountain Cancer Centers, Denver, CO;
12
Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA; and.
13
Sarah Cannon Research Institute, Nashville, TN.

Abstract

Carfilzomib, a proteasome inhibitor, is approved in the United States as a single agent, and in combination with dexamethasone or lenalidomide/dexamethasone (KRd) for relapsed or refractory multiple myeloma (MM). Under the single-agent and KRd approvals, carfilzomib is administered as a 10-minute IV infusion on days 1, 2, 8, 9, 15, and 16 of 28-day cycles (20 mg/m(2) [cycle 1, days 1-2]; 27 mg/m(2) thereafter). This multicenter, single-arm, phase 1/2 study, Community Harmonized Assessment of Myeloma Patients via an Integrated Oncology Network-1 (CHAMPION-1), evaluated once-weekly carfilzomib with dexamethasone in relapsed, or relapsed and refractory MM (1-3 prior therapies). Patients received carfilzomib (30-minute IV infusion) on days 1, 8, and 15 of 28-day cycles. The phase 1 portion used a 3 + 3 dose-escalation scheme to determine the maximum tolerated dose (MTD) of carfilzomib. During phase 2, patients received carfilzomib on the same schedule at the MTD. Patients received dexamethasone (40 mg) on days 1, 8, 15, and 22; dexamethasone was omitted on day 22 for cycles 9+. A total of 116 patients were enrolled. The MTD was 70 mg/m(2), and 104 patients (phase 1/2) received carfilzomib 70 mg/m(2) At 70 mg/m(2), the median number of prior regimens was 1; and 52% were bortezomib-refractory. At 70 mg/m(2), the most common grade ≥3 adverse events were fatigue (11%) and hypertension (7%). Overall response rate at 70 mg/m(2) was 77%. Median progression-free survival was 12.6 months. These findings merit additional evaluation of the once-weekly dosing regimen. This trial was registered at www.clinicaltrials.gov as #NCT01677858.

PMID:
27207788
PMCID:
PMC4929927
DOI:
10.1182/blood-2015-11-683854
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center